Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).

Clinical lymphoma, myeloma & leukemia - 1 Jul 2022

Chan Onyee, Ali Najla Al, Sallman David, Padron Eric, Lancet Jeffrey, Komrokji Rami

Abstract excerpt

BACKGROUND: Genetic alterations are increasingly being recognized to play an important role in both diagnosis and prognosis of MDS. In general, MDS patients with SF3B1 mutations (MT) are known to have favorable outcomes whereas those with TP53 mutations have dismal survivals. However, it is unclear if the impact of these mutations applies to all subtypes of MDS including del(5q) which is known for its response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Deletion
Share to Chromosomes, Human, Pair 5

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Myelodysplastic Syndromes

Share to Phosphoproteins

Share to RNA Splicing Factors

Share to Thalidomide

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 35101379
DOI: 10.1016/j.clml.2022.01.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).PMID 35101379Read ↗

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).Semantic proximity Read ↗

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.Semantic proximity Read ↗

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).Semantic proximity Read ↗

TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).Semantic proximity Read ↗

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Semantic proximity Read ↗

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings.Semantic proximity Read ↗

TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative casesSemantic proximity Read ↗

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Semantic proximity Read ↗

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)Semantic proximity Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

Deletion 5q MDS: molecular and therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.